| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
PIP4K2C (phosphatidylinositol 5-phosphate 4-kinase type-2 gamma); mTOR signaling pathway; membrane lipid organization.
|
|---|---|
| ln Vitro |
C24-Ceramide binds and activates PIP4K2C, promoting mTOR signaling activation in gallbladder cancer models. It induces time-dependent changes in membrane properties and membrane reorganization, increasing membrane order and permeability. As a competitive binding agonist of PIP4K2C, it drives downstream mTOR pathway activity and supports cancer cell progression, with functional effects observed in the low micromolar range in cell-based assays.
|
| ln Vivo |
In vivo, C24-Ceramide supports gallbladder cancer progression through PIP4K2C-dependent mTOR activation. Elevated C24-ceramide levels correlate with tumor growth and poor prognosis in gallbladder cancer, and pathway activation is observed in xenograft models. Its lipophilic nature requires formulation for systemic administration, and oral bioavailability has been reported for the PIP4K2C-agonist activity.
|
| Enzyme Assay |
For PIP4K2C binding assays, recombinant PIP4K2C is incubated with a fluorescent or radiolabeled phosphatidylinositol 5-phosphate probe and increasing concentrations of C24-Ceramide in assay buffer containing detergents to mimic membrane conditions. Bound ligand is separated by filtration or measured by fluorescence polarization, and Ki is derived from competition curves.
|
| Cell Assay |
For cell-based assays, gallbladder cancer cells or PIP4K2C-expressing lines are treated with C24-Ceramide (1–50 μM) for 24–72 h. mTOR pathway activation is assessed by phosphorylation of S6K1, 4E-BP1 and AKT by Western blot, and cell proliferation is measured by MTT or colony formation. Membrane order is assessed with Laurdan or di-4-ANEPPDHQ imaging.
|
| Animal Protocol |
For in vivo studies, mice bearing gallbladder cancer xenografts receive C24-Ceramide in a lipid formulation (e.g., 10–50 mg/kg, i.p. or oral) for 2–4 weeks. Tumor volume is monitored, and tumor tissue is analyzed for PIP4K2C activity, mTOR pathway phosphorylation and apoptosis by immunohistochemistry, with plasma and tissue ceramide levels quantified by LC-MS/MS.
|
| References | |
| Additional Infomation |
N-Tecosylsphingosine is an N-acylsphingosine in which the N-acyl group of the ceramide is designated as a tetracosyl group. It is a mouse metabolite. It is an N-acylsphingosine, Cer(d42:1), and N-(very long chain fatty acyl)sphingosine base. It is functionally related to tetracosyl acid.
|
| Molecular Formula |
C42H83NO3
|
|---|---|
| Molecular Weight |
650.113
|
| Exact Mass |
649.637
|
| CAS # |
102917-80-6
|
| Related CAS # |
C24-Ceramide;34435-05-7;C24-Ceramide-d7;1840942-15-5
|
| PubChem CID |
5283571
|
| Appearance |
White to off-white solid powder
|
| LogP |
13.074
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
38
|
| Heavy Atom Count |
46
|
| Complexity |
622
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@@H](/C=C/CCCCCCCCCCCCC)O
|
| InChi Key |
ZJVVOYPTFQEGPH-AUTSUKAISA-N
|
| InChi Code |
InChI=1S/C42H83NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(46)43-40(39-44)41(45)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,40-41,44-45H,3-34,36,38-39H2,1-2H3,(H,43,46)/b37-35+/t40-,41+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]tetracosanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5382 mL | 7.6910 mL | 15.3820 mL | |
| 5 mM | 0.3076 mL | 1.5382 mL | 3.0764 mL | |
| 10 mM | 0.1538 mL | 0.7691 mL | 1.5382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
